Identification and characterization of a novel botulinum neurotoxin

Nature Communications

Volumn 8, Issue , 2017, Pages

  Zhang, Sicai ^a   Masuyer, Geoffrey ^b   Zhang, Jie ^a   Shen, Yi ^a   Henriksson, Linda ^b   Miyashita, Shin Ichiro ^a   Martínez Carranza, Marke ^b   Dong, Min ^a   Stenmark, Paa ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; BOTULINUM TOXIN; BOTULINUM TOXIN X; PEPTIDES AND PROTEINS; SORTASE; SYNAPTOBREVIN 1; SYNAPTOBREVIN 2; UNCLASSIFIED DRUG; VESICLE ASSOCIATED MEMBRANE PROTEIN 4; VESICLE ASSOCIATED MEMBRANE PROTEIN 5; YKT6 PROTEIN; NEUROTOXIN; SYNAPTOBREVIN; VAMP4 PROTEIN, MOUSE;

BLOOD; CELLS AND CELL COMPONENTS; ENZYME; PROTEIN; TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENOME; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; FLACCID PARALYSIS; GENE EXPRESSION; GENE SEQUENCE; GENOME ANALYSIS; MOUSE; NERVE CELL CULTURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; RAT; AMINO ACID SEQUENCE; ANIMAL; BOTULISM; CHEMISTRY; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; MOLECULAR MODEL; PROTEIN MOTIF; SEQUENCE ALIGNMENT;

MUS;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; HUMANS; MICE; MODELS, MOLECULAR; NEUROTOXINS; R-SNARE PROTEINS; SEQUENCE ALIGNMENT; VESICLE-ASSOCIATED MEMBRANE PROTEIN 2;

EID: 85026563366     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14130     Document Type: Article

References (57)

1. Arnon, S. S. et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285, 1059-1070 (2001).
2. Johnson, E. A. Clostridial toxins as therapeutic agents: benefits of natures most toxic proteins. Annu. Rev. Microbiol. 53, 551-575 (1999).
3. Montecucco, C. & Molgo, J. Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. 5, 274-279 (2005).
4. Schiavo, G., Matteoli, M. & Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766 (2000).
5. Montal, M. Botulinum neurotoxin: A marvel of protein design. Annu. Rev. Biochem. 79, 591-617 (2010).
6. Rossetto, O., Pirazzini, M. & Montecucco, C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat. Rev. Microbiol. 12, 535-549 (2014).
7. Jahn, R. & Scheller, R. H. SNAREs-engines for membrane fusion. Nat. Rev. Mol. Cell Biol. 7, 631-643 (2006).
8. Sudhof, T. C. & Rothman, J. E. Membrane fusion: grappling with SNARE and SM proteins. Science 323, 474-477 (2009).
9. Burke, G. S. Notes on Bacillus botulinus. J. Bacteriol. 4, 555-570 (1919).
10. Gimenez, D. F. & Ciccarelli, A. S. Another type of Clostridium botulinum. Zentralbl Bakteriol. Orig. 215, 221-224 (1970).
11. Smith, T. J. et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73, 5450-5457 (2005).
12. Hill, K. K. et al. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J. Bacteriol. 189, 818-832 (2007).
13. Montecucco, C. & Rasotto, M. B. On botulinum neurotoxin variability. MBio. 6, e02131-e02134 (2015).
14. Dover, N., Barash, J. R., Hill, K. K., Xie, G. & Arnon, S. S. Molecular characterization of a novel botulinum neurotoxin type H gene. J. Infect. Dis. 209, 192-202 (2014).
15. Barash, J. R. & Arnon, S. S. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J. Infect. Dis. 209, 183-191 (2014).
16. Maslanka, S. E. et al. A novel botulinum neurotoxin, previously reported as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized with serotype A antitoxin. J. Infect. Dis. 213, 379-385 (2015).
17. Kalb, S. R. et al. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). Anal. Chem. 87, 3911-3917 (2015).
18. Zhou, Y., Sugiyama, H., Nakano, H. & Johnson, E. A. The genes for the Clostridium botulinum type G toxin complex are on a plasmid. Infect. Immun. 63, 2087-2091 (1995).
19. Marshall, K. M., Bradshaw, M., Pellett, S. & Johnson, E. A. Plasmid encoded neurotoxin genes in Clostridium botulinum serotype A subtypes. Biochem. Biophys. Res. Commun. 361, 49-54 (2007).
20. Jacobson, M. J., Lin, G., Raphael, B., Andreadis, J. & Johnson, E. A. Analysis of neurotoxin cluster genes in Clostridium botulinum strains producing botulinum neurotoxin serotype A subtypes. Appl. Environ. Microbiol. 74, 2778-2786 (2008).
21. Eklund, M. W., Poysky, F. T., Reed, S. M. & Smith, C. A. Bacteriophage and the toxigenicity of Clostridium botulinum type C. Science 172, 480-482 (1971).
22. Smith, T. J. et al. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS ONE 2, e1271 (2007).
23. Hill, K. K., Xie, G., Foley, B. T. & Smith, T. J. Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. Toxicon 107, 2-8 (2015).
24. Luquez, C., Raphael, B. H. & Maslanka, S. E. Neurotoxin gene clusters in Clostridium botulinum type Ab strains. Appl. Environ. Microbiol. 75, 6094-6101 (2009).
25. Dover, N. et al. Clostridium botulinum strain Af84 contains three neurotoxin gene clusters: bont/A2, bont/F4 and bont/F5. PLoS ONE 8, e61205 (2013).
26. Franciosa, G., Ferreira, J. L. & Hatheway, C. L. Detection of type A, B, and E botulism neurotoxin genes in Clostridium botulinum and other Clostridium species by PCR: evidence of unexpressed type B toxin genes in type A toxigenic organisms. J. Clin. Microbiol. 32, 1911-1917 (1994).
27. Hutson, R. A. et al. Genetic characterization of Clostridium botulinum type A containing silent type B neurotoxin gene sequences. J. Biol. Chem. 271, 10786-10792 (1996).
28. Dover, N., Barash, J. R. & Arnon, S. S. Identical novel A5(B3) botulinum neurotoxin gene arrangements isolated from widely disparate geographical and patient sources suggest their independent origins. J. Clin. Microbiol. 48, 1989 (2010).
29. Dabritz, H. A. et al. Molecular epidemiology of infant botulism in California and elsewhere, 1976-2010. J. Infect. Dis. 210, 1711-1722 (2014).
30. Kakinuma, H., Maruyama, H., Takahashi, H., Yamakawa, K. & Nakamura, S. The first case of type B infant botulism in Japan. Acta Paediatr. Jpn 38, 541-543 (1996).
31. Kozaki, S. et al. Characterization of Clostridium botulinum type B neurotoxin associated with infant botulism in japan. Infect. Immun. 66, 4811-4816 (1998).
32. Ihara, H. et al. Sequence of the gene for Clostridium botulinum type B neurotoxin associated with infant botulism, expression of the C-Terminal half of heavy chain and its binding activity. Biochim. Biophys. Acta 1625, 19-26 (2003).
33. Schiavo, G. et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832-835 (1992).
34. Rummel, A., Mahrhold, S., Bigalke, H. & Binz, T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51, 631-643 (2004).
35. Gu, S. et al. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335, 977-981 (2012).
36. Lee, K. et al. Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science 344, 1405-1410 (2014).
37. Lee, K. et al. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog. 9, e1003690 (2013).
38. Sugawara, Y. et al. Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. J. Cell Biol. 189, 691-700 (2010).
39. Rossetto, O. et al. SNARE motif and neurotoxins. Nature 372, 415-416 (1994).
40. Yamamoto, H. et al. Specificity of botulinum protease for human VAMP family proteins. Microbiol. Immunol. 56, 245-253 (2012).
41. Chaddock, J. A. et al. Expression and purification of catalytically active, non-Toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif. 25, 219-228 (2002).
42. Popp, M. W., Antos, J. M., Grotenbreg, G. M., Spooner, E. & Ploegh, H. L. Sortagging: A versatile method for protein labeling. Nat. Chem. Biol. 3, 707-708 (2007).
43. McCluskey, A. J. & Collier, R. J. Receptor-directed chimeric toxins created by sortase-mediated protein fusion. Mol. Cancer Ther. 12, 2273-2281 (2013).
44. Aoki, K. R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39, 1815-1820 (2001).
45. Binz, T., Bade, S., Rummel, A., Kollewe, A. & Alves, J. Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry 41, 1717-1723 (2002).
46. Pier, C. L. et al. Recombinant holotoxoid vaccine against botulism. Infect. Immun. 76, 437-442 (2008).
47. Steegmaier, M., Klumperman, J., Foletti, D. L., Yoo, J. S. & Scheller, R. H. Vesicle-Associated membrane protein 4 is implicated in trans-Golgi network vesicle trafficking. Mol. Biol. Cell 10, 1957-1972 (1999).
48. Brandhorst, D. et al. Homotypic fusion of early endosomes: SNAREs do not determine fusion specificity. Proc. Natl Acad. Sci. USA 103, 2701-2706 (2006).
49. Daste, F., Galli, T. & Tareste, D. Structure and function of longin SNAREs. J. Cell Sci. 128, 4263-4272 (2015).
50. Raingo, J. et al. VAMP4 directs synaptic vesicles to a pool that selectively maintains asynchronous neurotransmission. Nat. Neurosci. 15, 738-745 (2012).
51. Cocucci, E., Racchetti, G., Rupnik, M. & Meldolesi, J. The regulated exocytosis of enlargeosomes is mediated by a SNARE machinery that includes VAMP4. J. Cell Sci. 121, 2983-2991 (2008).
52. Nicholson-Fish, J. C., Kokotos, A. C., Gillingwater, T. H., Smillie, K. J. & Cousin, M. A. VAMP4 is an essential cargo molecule for activity-dependent bulk endocytosis. Neuron 88, 973-984 (2015).
53. Cooper, A. A. et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinsons models. Science 313, 324-328 (2006).
54. Thayanidhi, N. et al. Alpha-synuclein delays endoplasmic reticulum (ER)-To-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 21, 1850-1863 (2010).
55. Zeng, Q. et al. A novel synaptobrevin/VAMP homologous protein (VAMP5) is increased during in vitro myogenesis and present in the plasma membrane. Mol. Biol. Cell 9, 2423-2437 (1998).
56. Krzewski, K., Gil-Krzewska, A., Watts, J., Stern, J. N. & Strominger, J. L. VAMP4-And VAMP7-expressing vesicles are both required for cytotoxic granule exocytosis in NK cells. Eur. J. Immunol. 41, 3323-3329 (2011).
57. Peng, L., Tepp, W. H., Johnson, E. A. & Dong, M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 7, e1002008 (2011).